A new concept for the treatment of cancer

Crystal structure of human MTH1 in complex with a key inhibitor.<br />Source: Stockholm University, Prof. Pal Stenmark.

Crystal structure of human MTH1 in complex with a key inhibitor.
Source: Stockholm University, Prof. Pal Stenmark.

A team of researchers from five Swedish universities has identified a new way to treat cancer. They present their concept in the journal „Nature“. It is based on inhibiting a specific enzyme called MTH1. Cancer cells, unlike normal cells, need MTH1 to survive. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in the cancer cells. The research group at Stockholm University has determined the structure of MTH1 based on diffraction measurements at HZB´s MX-beamline at BESSY II. These detailed structural studies are important for the development of efficient inhibitors targeting MTH1.

In recent decades, the development of new anticancer agents focused on targeting specific genetic defects in cancer cells. These often are effective initially, but later cause trouble due to emerging rapid resistance. In the current study, the researchers present a general enzymatic activity that all cancers tested rely on and that seems to be independent of the genetic changes found in specific cancers. The research team shows that all the investigated cancer tumours need the MTH1 enzyme to survive. In this respect, cancer cells differ from normal cells, which do not need this enzyme.

“The concept is built on the fact that cancer cells have an altered metabolism, resulting in oxidation of nucleotide building blocks,” says Thomas Helleday, professor at Karolinska Institutet, who leads the study: "MTH1 repairs the oxidized building blocks, preventing the oxidative stress from being incorporated into DNA and becoming DNA damage. This allows replication in cancer cells so they can divide and multiply. With an MTH1 inhibitor, the enzyme is blocked and damaged nucleotides enter DNA, causing damage and killing cancer cells."

Normal cells do not need MTH1 as they have regulated metabolism preventing damage of nucleotide building blocks. Finding a general enzymatic activity required only for cancer cells to survive opens up a whole new way of treating cancer.

Original publication:
“MTH1 inhibition kills cancer by preventing sanitation of the dNTP pool”, Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth et al., Nature, online 2 April 2014, doi: 10.1038/nature13181. http://dx.doi.org/10.1038/nature13181.
“Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy”, Kilian V. M. Huber, Eidarus Salah, Branka Radic et al., Nature, online 2 April 2014, doi: 10.1038/nature13194. http://dx.doi.org/10.1038/nature13194

  • Copy link

You might also be interested in

  • Helmholtz Doctoral Award for Hanna Trzesniowski
    News
    09.07.2025
    Helmholtz Doctoral Award for Hanna Trzesniowski
    During her doctoral studies at the Helmholtz Centre Berlin, Hanna Trzesniowski conducted research on nickel-based electrocatalysts for water splitting. Her work contributes to a deeper understanding of alkaline water electrolysis and paves the way for the development of more efficient and stable catalysts. On 8 July 2025, she received the Helmholtz Doctoral Prize, which honours the best and most original doctoral theses in the Helmholtz Association.

  • New department at HZB: ‘AI and Biomolecular Structures’
    News
    07.07.2025
    New department at HZB: ‘AI and Biomolecular Structures’
    Since 1 July 2025, Dr. Andrea Thorn has been setting up the new AI and Biomolecular Structures department at HZB. A biophysicist with many years of experience in AI-based tools for structural biology, she is looking forward to collaborating closely with the macromolecular crystallography team at the MX beamlines of BESSY II.
  • Research up close! The Long Night of Science at HZB
    News
    20.06.2025
    Research up close! The Long Night of Science at HZB
    On 28 June, it's that time again: the Long Night of Science will take place from 5 pm to midnight  in Berlin and also in Adlershof! Come around and take a look behind the scenes of our exciting research.